EA201500514A1 - Продукт сомикронизации, включающий селективный модулятор рецептора прогестерона - Google Patents

Продукт сомикронизации, включающий селективный модулятор рецептора прогестерона

Info

Publication number
EA201500514A1
EA201500514A1 EA201500514A EA201500514A EA201500514A1 EA 201500514 A1 EA201500514 A1 EA 201500514A1 EA 201500514 A EA201500514 A EA 201500514A EA 201500514 A EA201500514 A EA 201500514A EA 201500514 A1 EA201500514 A1 EA 201500514A1
Authority
EA
Eurasian Patent Office
Prior art keywords
progesterone receptor
product
somicronization
receptor modulator
selective progesterone
Prior art date
Application number
EA201500514A
Other languages
English (en)
Other versions
EA029643B1 (ru
Inventor
Флориан Баттюн
Пьер-Ив Жувен
Жером Эк
Оде Колен
Original Assignee
Лаборатуар Хра-Фарма
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лаборатуар Хра-Фарма filed Critical Лаборатуар Хра-Фарма
Publication of EA201500514A1 publication Critical patent/EA201500514A1/ru
Publication of EA029643B1 publication Critical patent/EA029643B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Bidet-Like Cleaning Device And Other Flush Toilet Accessories (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Предметом настоящего изобретения является продукт сомикронизации, содержащий действующее вещество, выбранное из группы, состоящей из селективных модуляторов рецептора прогестерона, их метаболитов и их смесей, и полимерное вспомогательное вещество на основе N-винил-2-пирролидона. Изобретение также относится к фармацевтической композиции, содержащей указанный продукт со-микронизации, и их терапевтическому применению.
EA201500514A 2012-11-08 2013-11-07 Продукт сомикронизации, содержащий селективный модулятор рецептора прогестерона, способ его получения и фармацевтическая композиция на его основе EA029643B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1260605A FR2997628B1 (fr) 2012-11-08 2012-11-08 Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone
PCT/FR2013/052671 WO2014072647A1 (fr) 2012-11-08 2013-11-07 Produit de co-micronisation comprenant un modulateur selectif du recepteur a la progesterone

Publications (2)

Publication Number Publication Date
EA201500514A1 true EA201500514A1 (ru) 2015-09-30
EA029643B1 EA029643B1 (ru) 2018-04-30

Family

ID=47714259

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201500514A EA029643B1 (ru) 2012-11-08 2013-11-07 Продукт сомикронизации, содержащий селективный модулятор рецептора прогестерона, способ его получения и фармацевтическая композиция на его основе

Country Status (21)

Country Link
US (1) US20150258118A1 (ru)
EP (1) EP2916823B1 (ru)
JP (1) JP2015536969A (ru)
CN (1) CN105073098B (ru)
CR (1) CR20150298A (ru)
CY (1) CY1118884T1 (ru)
DK (1) DK2916823T3 (ru)
EA (1) EA029643B1 (ru)
EC (1) ECSP15022505A (ru)
ES (1) ES2625012T3 (ru)
FR (1) FR2997628B1 (ru)
GE (1) GEP201706648B (ru)
HR (1) HRP20170686T1 (ru)
LT (1) LT2916823T (ru)
MD (1) MD4546C1 (ru)
PL (1) PL2916823T3 (ru)
PT (1) PT2916823T (ru)
RS (1) RS55956B1 (ru)
SI (1) SI2916823T1 (ru)
UA (1) UA115573C2 (ru)
WO (1) WO2014072647A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106265533A (zh) * 2016-10-10 2017-01-04 朱隆娅 一种阿德呋啉颗粒剂及其制备方法
FR3060389B1 (fr) * 2016-12-20 2019-05-31 Laboratoire Hra-Pharma Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites
EP3895691A1 (en) 2020-04-15 2021-10-20 LTS Lohmann Therapie-Systeme AG Ulipristal acetate otf
US11878025B2 (en) 2021-09-06 2024-01-23 Slayback Pharma Llc Pharmaceutical compositions of mifepristone

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5759577A (en) * 1995-01-17 1998-06-02 American Home Products Corporation Controlled release of steroids from sugar coatings
JP2004099442A (ja) * 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
ES2212912B1 (es) * 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
JP5017109B2 (ja) 2004-07-09 2012-09-05 ザ・ポピュレイション・カウンシル，インコーポレイテッド プロゲステロン受容体モジュレーターを含有する徐放性組成物
SI2078032T1 (sl) * 2006-10-24 2017-12-29 Repros Therapeutics Inc. Sestave in postopki za zaviranje proliferacije endometrija
WO2008083192A2 (en) * 2006-12-28 2008-07-10 Repros Therapeutics Inc. Methods and formulations for improved bioavailability of antiprogestins
JP2008169135A (ja) * 2007-01-11 2008-07-24 Takada Seiyaku Kk グリメピリド組成物の製造方法
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
US8512745B2 (en) * 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
BRPI1014035A2 (pt) 2009-04-14 2016-04-12 Hra Pharma Lab método para contracepção.
EP2535114A4 (en) * 2009-11-13 2015-11-18 Moriroku Chemicals Company Ltd PROCESS FOR PRODUCING FINE POWDER AND FINE POWDER PRODUCED ACCORDING TO THIS METHOD
FR2988610B1 (fr) * 2012-03-30 2014-10-31 Effik Progestatif co-micronise avec un polymere portant le groupe pyrrolidone, composition et utilisations
CN102871977A (zh) * 2012-10-19 2013-01-16 北京紫竹药业有限公司 醋酸优力司特分散片及其制备方法

Also Published As

Publication number Publication date
CN105073098B (zh) 2019-02-19
RS55956B1 (sr) 2017-09-29
EP2916823A1 (fr) 2015-09-16
HRP20170686T1 (hr) 2017-09-08
CN105073098A (zh) 2015-11-18
EA029643B1 (ru) 2018-04-30
EP2916823B1 (fr) 2017-02-15
PT2916823T (pt) 2017-05-22
MD4546B1 (ru) 2018-01-31
FR2997628A1 (fr) 2014-05-09
MD4546B9 (ru) 2018-08-31
CY1118884T1 (el) 2018-01-10
PL2916823T3 (pl) 2017-08-31
UA115573C2 (uk) 2017-11-27
LT2916823T (lt) 2017-07-25
US20150258118A1 (en) 2015-09-17
MD4546C1 (ru) 2019-03-31
ES2625012T3 (es) 2017-07-18
JP2015536969A (ja) 2015-12-24
FR2997628B1 (fr) 2015-01-16
MD20150054A2 (ru) 2015-10-31
CR20150298A (es) 2015-08-14
DK2916823T3 (en) 2017-05-15
SI2916823T1 (sl) 2017-08-31
ECSP15022505A (es) 2016-01-29
WO2014072647A1 (fr) 2014-05-15
GEP201706648B (en) 2017-03-27

Similar Documents

Publication Publication Date Title
EA201500609A1 (ru) Твёрдая дисперсия селективного модулятора рецептора прогестерона
PH12014502414A1 (en) Novel compounds
CL2015002123A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
PH12015502621A1 (en) Estrogen receptor modulator and uses thereof
EA201270720A1 (ru) Модуляторы рецептора андрогенов и их применение
EA201370066A1 (ru) Модуляторы эстрогеновых рецепторов и их применение
AU2013225533A8 (en) Amido spirocyclic amide and sulfonamide derivatives
CL2014000956A1 (es) Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor.
BR112015018094A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
PE20151416A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
EA201300146A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ МОДУЛЯТОРА c-МЕТ
DOP2014000154A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BR112015018089A2 (pt) moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
EA201590953A1 (ru) Пирролидиновые модуляторы gpr40
BR112015018095A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
EA201591196A1 (ru) Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств
EA201291211A1 (ru) Фармацевтические композиции, содержащие гидроморфон и налоксон
EA201500514A1 (ru) Продукт сомикронизации, включающий селективный модулятор рецептора прогестерона
GT201400179A (es) Compuestos de cromano sustituidos como moduladores del receptor sensible al calcio
PH12019500949A1 (en) Ror-gamma modulators
EA201500513A1 (ru) Продукт сомикронизации, включающий ацетат улипристала
EA201400444A1 (ru) Производные 2-оксопиперидинила
EA201500313A1 (ru) Стабилизированная аморфная форма агомелатина, способ ее изготовления и фармацевтические композиции, ее содержащие
TH1401006422A (th) ตัวควบคุม ออร์แฟน รีเซฟเตอร์ ชนิดสัมพันธ์กับเรตินอยด์แกมมา (RORY) ชนิดใหม่ (novel retinoid-related orphan receptor gamma modulators), กระบวนการสำหรับการเตรียมของสิ่งนั้น, องค์ประกอบทางเภสัชกรรมที่บรรจุตัวควบคุมเหล่านี้ และการใช้ของสิ่งนั้น
UA111824C2 (uk) Лікарські форми рифаксиміну і їх застосування

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU